Status:
COMPLETED
Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer: Adjuvant DXP
Lead Sponsor:
Asan Medical Center
Conditions:
Resected Advanced Gastric Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Despite the improvement of surgical resection as primary curative treatment for gastric cancer, more than 70% of patients with stage IIIB and IV disease undergoing radical primary tumor resection rela...
Detailed Description
Previous in phase II study of docetaxel, capecitabine and cisplatin,total 40 pts with measurable disease, median 6 cycles of chemotherapy, there were 4 confirmed complete responses (CRs) and 23 confir...
Eligibility Criteria
Inclusion
- Histologically or cytologically documented gastric adenocarcinoma
- Age 18 -70
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Pathologic stage IIIB or IV
- complete resection (R0 resection)
Exclusion
- Other tumor type than adenocarcinoma
- R1 or R2 resection
- Presence of distant metastasis
- Gastric outlet obstruction or intestinal obstruction
- Evidence of gastrointestinal bleeding
- Other serious illness or medical conditions
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00976976
Start Date
May 1 2007
End Date
September 1 2011
Last Update
January 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, Songpa-gu, South Korea, 138-736